Inhibition of Androgen Receptor Exposes Replication Stress Vulnerability in Prostate Cancer
Williams, C. S.; Li, X.; Jang, H.; Anand, J. R.; Lim, W. Y.; Lee, H.; Parks, J.; Zhang, X.; Xie, J.; Zhao, J.; Wu, D.; Armstrong, A. J.; Bowser, J. L.; Zou, L.; Hong, J.; Somarelli, J. A.; Vaziri, C.; Zhou, P.
Show abstract
Standard initial systemic treatment for patients with metastatic prostate cancer includes agents that target androgen receptor (AR) signaling. Despite an initial positive response to these AR pathway inhibitors (ARPIs), acquired resistance remains a significant challenge. We show that treatment of AR-positive prostate cancer cells with the frontline ARPI enzalutamide induces DNA replication stress. Such stress is exacerbated by suppression of translesion DNA synthesis (TLS), leading to aberrant accumulation of single-stranded DNA (ssDNA) gaps and persistent DNA damage biomarkers. We further demonstrate that the TLS inhibitor, JH-RE-06, markedly sensitizes AR-positive prostate cancer cells, but not AR-negative benign cells, to enzalutamide in vitro. Combination therapy with enzalutamide and JH-RE-06 significantly suppresses cancer growth in a syngeneic murine tumor model over vehicle control or individual treatment groups. These findings suggest that AR inhibition broadly triggers DNA replication stress in hormone-sensitive prostate cancer, thereby exposing a unique vulnerability that can be exploited by a TLS-disrupting adjuvant for targeted therapy.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Suppression of tumor cell lactate-generating signaling pathways eradicates murine PTEN/p53-deficient aggressive-variant prostate cancer via macrophage phagocytosis 94%
- Reversal of lactate and PD-1-mediated macrophage immunosuppression controls growth of PTEN/p53-deficient prostate cancer 94%
- Assessment of Androgen Receptor splice variant-7 as a biomarker of clinical response in castration-sensitive prostate cancer 93%
Similar papers in this journal
- Brd4-bound enhancers drive cell intrinsic sex differences in glioblastoma 92%
- Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer 91%
- Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells 91%
Similar papers in this journal
- BET inhibition sensitizes immunologically-cold Rb-deficient prostate cancer to immune checkpoint blockade 94%
- Targeting the PI3K/AKT pathway overcomes enzalutamide resistance by inhibiting induction of the glucocorticoid receptor 93%
- Small molecule mediated stabilization of PP2A modulates the Homologous Recombination pathway and potentiates DNA damage-induced cell death 92%
Similar papers in this journal
- Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancer 92%
- Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma 92%
- Base Excision Repair Pathway Regulates Transcription-Replication Conflicts in Pancreatic Ductal Adenocarcinoma 91%
Similar papers in this journal
- TNF Blockade Reduces Prostatic Hyperplasia and Inflammation while Limiting BPH Diagnosis in Patients with Autoimmune Disease 93%
- Transcriptional network involving ERG and AR orchestrates Distal-Less Homeobox 1 mediated prostate cancer progression. 92%
- FOXJ1 mediates taxane resistance through regulation of microtubule dynamics 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.